Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment
| Autor: | Rosalind Ramsey-Goldman, J. Romero-Diaz, Daniel J. Wallace, Ann E. Clarke, M. Petri, Dafna D. Gladman, Sasha Bernatsky, Edward H. Yelin, William D. Foulkes, Ellen M. Ginzler, Sang Cheol Bae, B. Tessier Cloutier, Ola Nived, Paul R. Fortin, Murray B. Urowitz, K. Chan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Receptor Status medicine.drug_class Receptor ErbB-2 medicine.medical_treatment Population Estrogen receptor Breast Neoplasms Cohort Studies 03 medical and health sciences 0302 clinical medicine Breast cancer Rheumatology Internal medicine medicine Humans Lupus Erythematosus Systemic skin and connective tissue diseases education Receptor 030203 arthritis & rheumatology education.field_of_study Chemotherapy business.industry Carcinoma Ductal Breast Middle Aged medicine.disease Radiation therapy Receptors Estrogen Estrogen 030220 oncology & carcinogenesis Female business Receptors Progesterone |
| Zdroj: | Lupus. 27(1) |
| ISSN: | 1477-0962 |
| Popis: | Objective There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|